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SUMMARY 
 
Objectives 
To describe the histopathological (macro- and microscopic) findings in placentae of 
mothers with HIV and to investigate the influence of maternal ARV therapy on 
histopathology, as well as to investigate the influence of immune suppression (CD4 count) 
on histopathology. 
 
Methods 
A retrospective audit of placentae collected between 2009 and 2010 from mothers with 
HIV disease was performed. Placentae were examined according to the standard protocol 
used by the Division of Anatomical Pathology (Appendix B). Data were extracted from the 
files and reports by the MMed student and loaded onto a database in a strictly anonymous 
fashion.  Women with HIV plus co-morbidities specifically affecting placental function such 
as diabetes mellitus and pre-eclampsia were noted but not excluded from the study. 
 
Results 
There were 200 HIV cases that were identified during the study.  Of the 200 cases 196 
had histopathology results.  The main placental findings in the study were that of maternal 
vascular under-perfusion (36%), ascending infection (29%) including chorioamnionitis and 
small placenta (15%).  However, there was no significant difference in pathological 
diagnostic groups between the CD4 counts of the less than or greater than 350 cells/mm3. 
 
Conclusion 
Maternal vascular under-perfusion, ascending infection and small placenta may be linked 
to HIV placental infection, but further higher powered, controlled studies need to be done. 
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OPSOMMING 
 
Mikpunte 
Om die histopatologiese (makro- en mikroskopies) bevindinge in plasentas van moeders 
met HIV te omskryf en die invloed van moederlike ARV terapie op histopatologie te 
ondersoek, asook die invloed van immuun onderdrukking (CD4 telling) op histopatologie 
te ondersoek. 
 
Metodes 
‘n Retrospektiewe oudit van plasentas wat gedurende 2009 en 2010 gekollekteer is van 
moeders met HIV is uitgevoer. Plasentas is ondersoek deur gebruik te maak van die 
standaard protokol wat deur die Afdeling Anatomiese Patologie gebruik word (Aanhangsel 
B). Data is deur die MMed student versamel uit leêrs en verslae en op ‘n databasis gelaai 
op ‘n streng anonieme wyse.  Vroue met HIV en ko-morbiditeite soos diabetes en 
preëklampsie, wat spesifiek plasentale funksie affekteer, is opgeteken maar nie uitgesluit 
van die studie nie. 
 
Resultate 
Daar is 200 HIV gevalle gedurende die studie geïdentifiseer.  Uit 200 gevalle het 196 
histopatologie resultate gehad.  Die hoof plasentale bevindinge in die studie was 
moederlike vaskulêre onder-perfusie (36%), opstygende infeksie (29%) insluitende 
chorioamnionitis en klein plasenta (15%).  Nietemin was daar geen merkbare verskil in 
patologies diagnostiese groepe tussen die CD4 telling van minder as of meer as  
350 selle/mm3. 
 
Gevolgtrekking 
Moderlike vaskulêre onder-perfusie, opstygende infeksie en klein plasenta mag verbind 
word met HIV plasentale infeksie, maar verdere groter gekontrolleerde studies moet 
gedoen word. 
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CHAPTER 1: INTRODUCTION 
 
Currently there are more than 33 million individuals who are living with the Human Immuno 
Deficiency Virus (HIV) worldwide [1]. 
 
HIV prevalence is estimated to be 29.4% to 30% amongst pregnant women in South Africa 
and Mother-to-Child Transmission rates (MTCT) range from 15 to 40 % if no antiretroviral 
medication (ARV) is administered. With the advent of ARV’s, the MTCT rate has been 
reduced to less than 2% in some parts of the country [1]. 
 
Most transmission is believed to occur at birth and the various factors influencing this 
event include viral load, CD4 count, genotype of the virus, ARV’s and obstetric factors 
such as prolonged rupture of membranes. Vaginal delivery has been associated with 
increased transmission of the virus as opposed to planned elective delivery by Caesarean 
section [2]. 
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CHAPTER 2: LITERATURE REVIEW 
 
2.1 HIV 
 
The 2012 world UNAIDS day report highlighted that 30 million individuals globally are 
aware of their HIV status, with 2.5 million new cases of infection.  Of these 30 million, 14.8 
million people qualified for antiretroviral (ARV) treatment and 8 million were already on 
ARV medication [3]. 
 
Latest data regarding the global distribution of the disease, shows that 4.8 million 
individuals are infected with the virus in Asia, 2.3 million in North America, 1.4 million in 
Europe, 1.4 million in Latin America and 23.5 million in sub-Saharan Africa.  South Africa 
currently has the highest prevalence with 5.6 million people living with the virus.  There 
are approximately 1.7 million people on antiretroviral therapy in South Africa [3]. 
There are two subtypes of HIV, namely Type 1 and Type 2.  HIV 1 is more prevalent 
globally whilst type 2 is more common in West Africa.  Mother-to-child-transmission 
(MTCT) or vertical transmission may occur in utero during the intrapartum period due to 
exposure to maternal blood and fluids at delivery and post-partum during breastfeeding.  
HIV 1 has been closely linked to vertical transmission while HIV 2 has not been associated 
with this process [1]. 
 
Sub-Saharan Africa is plagued by the HIV 1 virus which is most commonly acquired 
heterosexually. It is however encouraging to note that in South Africa, the prevalence in 
the 15 to 24 year group has declined by 35% [3].  This may be attributed to an effective 
HIV awareness program as well as the availability of ARV’s to the affected pregnant 
population, thereby decreasing the MTCT rate.  Hence, more children are born HIV 
negative.  Prior to antiretroviral therapy the achievement of uncomplicated pregnancies 
was challenging. Women with non-pregnancy related infections experienced increased 
mortality, which has since decreased by 25% compared to the period of 2002-2004 [4]. 
 
Stellenbosch University  https://scholar.sun.ac.za
3 
 
In South Africa in 2010, 30.2% of women attending antenatal clinics were living with the 
virus.  In the Western Cape Province the prevalence amongst pregnant women was 
18.5%.  The overall HIV prevalence for the Western Cape in 2008 was 3.8%. (South 
African HIV statistics 2002 to 2008).  Currently in South Africa more than 95% of HIV 
positive pregnant women are receiving ART (antiretroviral therapy).  This has led to a 
decrease in MTCT.  However, there were still 29 100 newly infected children in the year 
2012.  It should be noted that vertical transmission rates range between 25 to 45% in the 
untreated population [5]. 
 
With more women now being on antiretroviral treatment, clinicians are required to address 
the “cause and effect” picture of HIV - the effect of HIV on the placenta, the influence of 
the maternal CD4 cell count and viral load (surrogate markers), the effects of antiretroviral 
treatment on the placenta and also the outcome of the babies born to HIV positive 
mothers.  A CD4 count of more than 400/mm3 of blood is associated with a low risk of 
vertical transmission.  When the CD4 count is 200 to 400mm3, there is a moderate 
transmission risk and when it is less than 200 there is an associated higher risk of 
transmission and complications related to maternal HIV infection [6]. 
 
Most of the HIV transmission happens around the time of parturition via transplacental 
HIV transmission or during labour when the fetus comes into contact with maternal blood 
in the birth canal.  Extensive work has been done to reduce MTCT during labour.  
Advanced HIV infection is associated with poor fetal and maternal outcomes.  Some 
studies suggest that there is an association between advanced HIV infection and 
miscarriage, intrauterine foetal growth restriction, preterm delivery and perinatal mortality 
[7,8,9]. In certain protocols, Zidovudine (AZT) has been favoured as it inhibits HIV replication 
within placental cells and this has decreased placental/in-utero HIV transmission.  
Patients on AZT have been shown to have normal placentas with favorable fetal 
outcomes. The risk of chorioamnionitis, chorangiosis and chronic villitis was less in the 
population receiving AZT [10] 
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Studies suggest that an ailing immune system with a low CD4 count and a viral load of 
more than 1000 copies does increase MTCT rates [2].  On the other hand, a near normal 
CD4 count with a low viral load (less than 1000 copies), has a transmission rate of 1% [6].  
This seems to be a protective factor and is the basis for the widespread use of ARVs in 
pregnancy. Preterm delivery, vaginal delivery, mixed feeding (formula and breast), 
antepartum invasive procedures, chorioamnionitis, hepatitis infection, illicit drug use 
especially cocaine have been postulated to increase the risk of vertical transmission.  
However, the advent of ARVs has brought significant improvements in maternal and 
neonatal outcomes [11].  ARVs help decrease the amount of the HI virus in the body; this 
decreases the risk of vertical transmission and also leads to improved maternal health. 
 
There are six classes of antiretroviral medication, namely: 
 Entry inhibitors:  Interfere with the ability of the virus to bind to receptors in the 
outer surface of the cell; this prevents HIV from entering the cell. 
 Fusion inhibitors:  Prevent the virus from fusing with the cellular membrane. 
 Reverse transcriptase inhibitors– RTI:  Inhibitors to double stranded HIV DNA 
(deoxyribose nucleic acid). 
o Nucleoside – NRTI: these drugs are analogues to the deoxynucleotides 
needed to form the viral DNA. They however lack the hydroxyl group on the 
deoxyribose moiety and this leads to chain termination if there is 
incooperation with viral DNA, thus halting viral DNA formation.  
o Non-nucleoside – NNRTI:  (bind to the enzyme reverse transcriptase and 
inhibits it from converting viral RNA to DNA). 
 Integrase inhibitors:  Block the enzyme HIV Integrase, which integrates the viral 
DNA to the host cell. 
 Protease inhibitors (PI):  These affect the protease enzyme which is responsible 
for assembling the new virion, and blocks HIV replication. 
 Multi class combination products:  The use of two or more of the classes is 
accepted as it reduces drug resistance [12]. 
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The main classes of antiretroviral drugs used in pregnancy are nucleoside reverse 
transcriptase inhibitors (NRTI), e.g. Zidovudine.  The main concern with this group is lactic 
acidosis which has a high mortality rate.  Other side effects include anemia, gastro-
intestinal and dermatological manifestations such as skin rashes, skin colour changes 
(hyperpigmentation), hypertrichoisis, pruritus, toxic epidermal necrolysis, bluish- brown 
coloured hands and nails and Stevens- Johnson syndrome.  The non-nucleoside reverse 
transcriptase inhibitors (NNRTI) class e.g. Nevirapine (NVP) and Efivarenz (EFV) inhibits 
the reverse transcriptase enzyme.  EFV has been associated with teratogenicity.  Neural 
tube and central nervous system abnormalities have been shown to be the commonest 
abnormalities in the first trimester animal models as well as retrospective human case 
reports as neural tube closure occurs at day 25 of development [12].  This drug has since 
been classified as a category D drug by the Food and Drug Administration (FDA), which 
means that it is not safe or recommended in pregnancy [13].  “Nevirapine is associated with 
dermatological complications such as Stevens-Johnsons syndrome and hepatic toxicity.  
Protease inhibitors (PIs) e.g. Kaletra have been associated with diabetes mellitus and 
lipodystrophy and have therefore fallen out of favour.  The combination of Emtricitabine 
together with Tenofovir (TDF) (NRTIs) as a single dose regimen has also been associated 
with lactic acidosis and hepatomegaly.”[12] In fact most ARVs have potentially serious side 
effects.  For this reason the clinician must be able to triage patients appropriately to the 
various regimens in order to decrease these side effect profiles which, if neglected, may 
lead to poor compliance and/or complications. 
 
Initially monotherapy with AZT was the regimen of choice for reducing vertical 
transmission of HIV.  Thereafter, combination therapy was used because monotherapy 
was shown to pose a higher risk of drug resistance than combination therapy [5].  
Combination therapy also showed a greater reduction in rates of transmission, even if 
started in the second or early third trimester.  In South Africa there is an extremely high 
prevalence of HIV positivity in pregnancy.  The public sector is not in a position to offer all 
HIV positive women an elective caesarean section to decrease vertical transmission.  
Combination therapy has in this sense “given” most women the option of a vaginal delivery 
with reduced risks of transmission especially in the group with undetected viral load [2].  
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The public sector can currently not afford to offer planned elective caesarean section to 
high risk HIV positive women due to cost. 
 
In a large prospective study of 2 543 pregnant HIV infected women, monotherapy was 
compared to combination therapy. Tuomala et.al, found that combination therapy with PIs 
increased the risk of preterm delivery without differences in birth weight and still birth rates 
[14].  A similar study published by Thorne et.al, in 2012, investigated 4372 pregnancies 
exposed to HIV and HAART.  They reported an increased rate of prematurity of up to 
24.9% in the protease inhibitor group of ARVs and thus an increase in the mortality rate 
[15].  This raises concerns about the safety of various combinations of antiretroviral 
medications. Clinicians must constantly and systematically assess which agents and 
combinations give the best results in pregnancy.  The goal is always to have the smallest 
number of adverse outcome for the mother and her fetus.  However, Lambert et.al. found 
that exposed and treated women compared to non-exposed women had similar risk 
factors with respect to adverse pregnancy outcomes.  They suggested that prenatal care 
and ARV medication would reduce adverse pregnancy outcomes [16].  There is much 
conflict of opinion displayed in the research arena with regards to antiretroviral treatment 
and this is fueled by the ever increasing amount of new information on the HIV. 
 
Studies undertaken in Botswana investigated the association of HIV transmission in 
women on Highly Active Antiretroviral Therapy (HAART) and the risk of stillbirth.  It was 
concluded that ‘in-utero HIV infection was rarely associated with stillbirths and did not 
occur in those receiving HAART’ [17].  The stillbirths in this study were mainly associated 
with hypertension and placental insufficiency.  A further question that still needs to be 
definitively answered is whether there is a link between pre-eclampsia and treatment with 
HAART.  In a prospective cohort study published by Hall and colleagues in 2014, pre-
eclampsia and gestational hypertension was less common in HIV infected women being 
managed on mono or triple antiretroviral therapy [18]. 
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2.2 The placenta 
 
The placenta is a fetal organ which also affects the mother, providing functions such as 
gaseous exchange, excretion, maintenance of homeostasis, hormone secretion, 
hemopoeisis and hepatic metabolic functions [19]. The placenta comprises the 
parenchyma, membranes and the umbilical cord. It records all fetal and maternal changes 
and also serves as an endocrine gland and a gaseous exchange organ for the developing 
fetus. 
 
The formation of the placenta and membranes is completed by the 12th to 13th week of 
pregnancy. Following implantation, the fetoplacental unit develops from hemangioblastic 
cells. These merge together to form primitive capillary vessels and under the influence of 
vascular endothelial growth factor (VEGF) and placental growth factor (PIGF), multiply to 
form an elaborate vessel network [20].  While it is clear that placental abnormalities may 
lead to fetal demise and maternal illness (as in the case of pre-eclampsia), the converse 
is also true.  Maternal illness such as hypertension and auto-immune diseases may lead 
to placental dysfunction with associated adverse outcomes [18].. 
 
It is important to note that the effects of HIV on the placenta are still not well understood. 
The placenta is thought to have a protective role against HIV transmission to the fetus.[21]  
‘Thus there is heightened interest in determining whether there are differences in the 
spectrum of placental lesions, particularly inflammatory lesions, between HIV-infected and 
-uninfected women and whether specific lesions are related to an increased risk of 
perinatal HIV transmission[22].  Currently, there are no clear answers to these questions 
because the number of studies is small and findings on the effects of HIV on the placenta 
differ. The most common inflammatory lesion is chorioamnionitis observed in a third of 
cases. The most common non-inflammatory lesion is cytotrophoblastic hyperplasia, 
observed in about ¾ of the cases. Antiretroviral therapy does not diminish the incidence 
of these lesions [23].  However, additional studies report either no or few placental 
differences to be associated with HIV.  In a prospective study undertaken by Vermaak 
et.al, at Tygerberg Academic Hospital in the Western Cape Province of South Africa, 
Stellenbosch University  https://scholar.sun.ac.za
8 
 
placentae from the HIV-positive pregnancies were characterized by decreased weight and 
an increased number of marginal infarcts in comparison to HIV-negative pregnancies.  
The most important microscopic finding in that study was the increased presence of villitis 
of unknown etiology (VUE) among the group of untreated HIV-positive women with CD4 
cell counts of < 200 cells/mm3 [24]. 
 
A small prospective study was performed by D’Costa et al., in Mumbai (2006), where 51 
placentae from HIV positive women were examined and compared with a matched control 
group from HIV negative women. The most common inflammatory lesion detected was 
chorioamnionitis (31.37%) while the dominant non-inflammatory lesion was 
cytotrophoblastic hyperplasia (76.47%). They concluded that, ‘there was no significant 
decrease in the incidence of lesions following treatment with ARVs and there was no 
correlation between placental lesions and HIV in the newborn’ [25]. 
 
Amirnessami-Aghili et al. showed that the trophoblastic cells of human placenta tissue 
express CD4 antigen and are susceptible to HIV-1 infection.  They also demonstrated that 
the placental endocrine function is decreased in HIV-1 infection.  Thus, the placenta may 
serve as a reservoir of HIV-1 infection during pregnancy, contributing to infection of the 
fetus, and decreased placental hormone production may result in impaired fetal 
development [26]. 
 
Indications for placental examination vary between sites, but there are published 
guidelines from the Royal College of Pathologists developed together with the British 
Paediatric Pathology Association (BRIPPA), Royal College of Obstetricians and 
Gynaecologists (RCOG), The Royal College of Paediatrics and Child Health (RCPCH) 
and the Royal College of Midwives. ‘All placentas from stillbirths, intrauterine growth 
restriction (below 3rd centile), immaturity, cases of severe fetal distress requiring 
admission to a neonatal intensive care unit (NICU) and late miscarriages should be 
referred’[27] .These may be adapted to local needsprior to consultation with all 
stakeholders. The indications used at Tygerberg Academic Hospital based on these 
guidelines are included as Appendix C.  It is currently uncertain whether placental 
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examination should be performed on uncomplicated HIV positive deliveries.  This 
uncertainty exists due to the paucity of scientific information, but anecdotal cases and 
limited studies in South Africa suggest these mothers and babies might represent an “at 
risk” population. 
 
In Tygerberg Academic Hospital, approximately 1400 HIV positive pregnancies are 
managed annually.  In 2012, unpublished data showed that 1379 HIV positive patients 
were managed, of whom 731 were on HAART and 648 on other combinations to prevent 
vertical transmission.  Patients not receiving HAART generally received AZT from 14 
weeks gestation (or later) as well as Nevirapine and Truvada® (Emtricitabine and TDF) 
intrapartum.  During the same year, there were 1343 live births and 107 stillbirths.  This 
high stillbirth rate highlights the need for placental examination. It is important to ascertain 
whether the risk of stillbirth is independent or dependent on HIV infection.  Another factor 
that must be kept in mind is that patients presenting to a tertiary academic institution such 
as Tygerberg Academic Hospital have other related or independent co-morbidities.  For 
this reason it should be established whether the risk of stillbirth is related to the various 
complex maternal diseases alone or is associated with HIV infection as well. It has already 
been mentioned that a study performed in Botswana indicated that stillbirths had a greater 
association with maternal hypertensive disease rather than HIV infection of the mother 
[17].  These findings may be different in an urban academic hospital such as Tygerberg 
Academic Hospital.  A study performed by Kennedy et.al.in an urban but secondary 
hospital located in the same city as Tygerberg Academic Hospital, found HIV infected 
pregnancies to be associated with significantly higher rates of stillbirth, antepartum 
hemorrhage, intra-uterine growth restriction and chorioamnionitis in the exposed group 
[28]. 
 
Finally, Chandwani and colleagues in a small prospective study of 20 placentae, 
examined the expression of HIV in placentas of seropositive women. They found that there 
was an increase in chorioamnionitis in HIV exposed placentas as opposed to the non-
exposed placentae. However, they did not find villitis to be a significant finding.  HIV 
antigens were found in 10% of placentae which harbored chorionitis, this was attributed 
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to the direct effect of HIV or co-existence with other infection [29]. This supports the 
postulate that chorioamnionitis is higher in the HIV exposed pregnancy. 
 
There is paucity of scientific information in relation to the effect of HIV on the 
histopathology of the placenta. Tygerberg Academic Hospital has a high level of expertise 
and there is close co-operation between the Department of Obstetrics and Gynaecology 
and the Division of Anatomical Pathology.  This team was therefore ideally placed to 
investigate this association further.  The formal aim of this study was to investigate 
placental changes related to HIV infection and to correlate these with maternal 
characteristics and neonatal outcomes. 
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Chapter 3: Research methodology 
 
3.1 Study setting 
 
This retrospective, descriptive study was performed at Tygerberg Academic Hospital in 
the Western Cape province of South Africa.  Patients requiring secondary and tertiary 
care from the Metro East region of Cape Town are referred to this centre for specialist 
management. 
 
3.2 Aim 
 
To investigate placental changes related to HIV infection and to correlate these with 
maternal characteristics and neonatal outcomes. 
 
3.3 Objectives 
 
 To describe the histopathological (macro- and microscopic) findings in placentae of 
mothers with HIV. 
 To investigate the influence of maternal ARV therapy on histopathology. 
 To investigate the influence of immune suppression (CD4 count) on histopathology. 
 
3.4 Methods 
 
A retrospective audit was performed on placentae collected between 2009 and 2010 
(1400 cases) from mothers with HIV disease.  Placentae were examined according to the 
standard protocol used by the Division of Anatomical Pathology (Appendix B).  Data were 
extracted from the files and reports by the MMed student and loaded onto a database in 
a strictly anonymous fashion.  Women with HIV and co-morbidities specifically affecting 
placental function such as diabetes mellitus and pre-eclampsia were noted but not 
excluded from the study. Maternal and neonatal data were extracted from the hospital 
files by Dr M Zungu (the primary investigator).  This data was transferred to an anonymous 
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(only study numbers used) spread sheet by the primary investigator. The detailed 
pathology reports on the placentas were coordinated by Dr Schubert and then added to 
the data sheet by Dr Zungu. 
Cases that were excluded included women with unknown HIV status, multiple 
pregnancies and stillborn babies at less than 26 weeks’ gestation, as well as miscarriages.  
The data sheet is provided as Appendix C.  
 
3.5 Sample size 
 
One thousand, four hundred files were available. Of the available files 200 were eligible 
for review and 196 qualified for inclusion in the study. 
 
3.6 Data analysis 
 
The statistical analysis was performed together with Prof M Kidd of the Research and 
Support Division. STATA version 13 was used for data analysis [30].  Variables were tested 
for associations using cross tabulation and Chi square test.  Summary statistics were 
reported as medians (with range) and frequencies with percentages. Where indicated 
descriptive statistics alone were used for data description. For summary purposes, the 
summary statistics including histograms, frequency tables, means and standard 
deviations were calculated.   
Where indicated, the following tests were used: 
 Mann-Whitney test for categorical variables 
 Fisher’s exact test for categorical variables less than ten  
 Kruskal-Wallis ANOVA for categorical variables with more than two categories. 
A p-value of p<0.05 was used to determine statistical significance.  
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3.7 Ethical considerations 
 
The protocol was submitted to the Research Ethics Committee of Stellenbosch University 
and thereafter Tygerberg Academic Hospital for approval (SU study No. S12/01/011).  No 
patient identifying data were used on the data capture sheet.  A waiver of consent was 
requested for this retrospective, anonymous audit.  Only the primary investigator retained 
a patient identification log, as a separate document, in a secure location.  This audit 
contains no deviation from standard clinical practice. 
 
3.8 Anticipated benefits 
 
The results should broaden our understanding of perinatal outcomes and of transmission 
of HIV disease. 
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CHAPTER 4: RESULTS 
 
During the defined study period 1400 files were reviewed and 200 cases with documented 
maternal HIV seropositive status were identified with their placental histology reports.  
Three cases with twins were excluded due to difficulties in reporting various types of 
placentae accurately.  The final number of placentae for the study was therefore 197.  The 
descriptive data from the files of the HIV positive mothers is shown in Table 1. 
 
Table 1:  Maternal descriptive profile 
Characteristic  Median (range) or n (%) 
Age  27 (15-46) 
Gravidity  2 (1-7) 
Parity  1 (0-6) 
BMI 28 (14-47) 
CD4 count   
<350 n (%) 
≥350 n (%) 
306 (14-1108) 
92 (46.9) 
104 (53.1) 
Antiretroviral medication n (%) 
NIL 
HAART 
PMTCT 
 
39 (19.8) 
63 (32.0) 
95 (48.2) 
Smoking n (%) 24 (12.2) 
CD4 = T-helper lymphocytes per cubic millimeter of blood; BMI= body mass index; 
HAART = highly active antiretroviral therapy; PMTCT = prevention of mother to child transmission 
 
The important clinical conditions identified in this group are shown in Table 2.  
Tuberculosis was found in four patients all of whom had a CD4 count of <350 cells/mm3.  
Two of these patients had not received antiretroviral medication while the other two 
received PMTCT and HAART respectively. 
 
  
Stellenbosch University  https://scholar.sun.ac.za
15 
 
Table 2:  Clinical conditions 
Conditions CD4 count/mm3 P value ARVs 
 CD4<350 CD4≥350  HAART PMTCT Nil 
Pre-eclampsia 21 21 0.84 15 (35.7) 16 (38.1) 11 (26.2) 
Diabetes 
mellitus 
0 3 0.28 0 0 3 (100) 
Tuberculosis 4 0  1 (25) 1 (25) 2 (50) 
None 72 (78.3) 80 (76.9) 0.11 48 (31.6) 79 (52.7) 25 (16.4) 
Data given as n (%); Patient may have > 1 condition.  Statistical comparisons were performed on clinical 
conditions and CD4 counts (<350 vs ≥350/mm3) as well as clinical conditions and forms of therapy (HAART 
vs no therapy; HAART vs PMTCT; PMTCT vs no therapy and any therapy vs no therapy), but no statistically 
significant differences were found. 
 
In the pre-eclampsia group shown in Table 2, 15 women received HAART, 16 PMTCT, 
while 11 received no treatment prior to delivery.  With regard to the women in Table 2 
where no significant clinical conditions (co-morbidities) were noted 48 received HAART, 
79 PMTCT while 25 received no treatment prior to delivery.  None of the groups, including 
HAART and PMTCT together were significantly different from each other in the “no co-
morbidity” group in Table 2. 
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The specified cluster diagnoses noted on placental examination are shown in Table 3. 
 
Table 3:  Pathological diagnoses: macro- and microscopic features according to 
cluster diagnoses and CD4 count 
Cluster diagnoses CD4 count/mm3 Total (%) p-value 
 CD4<350 CD4≥350 
Maternal vascular under 
perfusion (MVUP) 
35 (50) 35 (50) 70 (36) 0.70 
Placental insufficiency 1 (16.7) 5 (83.3) 6 (3) 0.26 
Placental abruption* 6 (35.3) 11 (64.7) 17 (9) 0.43 
Ascending infection 30 (51.7) 28 (48.3) 58 (29) 0.54 
Hematogenous infection 5 (83.3) 1 (16.7) 6 (3) 0.36 
Immunological damage 0 1 (100) 1 (0.5)  
Small placenta 11 (36.7) 19 (63.3) 30 (15) 0.28 
Normal/ no pathology 6 (66.7) 3 (33.3) 9 (5) 0.44 
Data given as n (%); Small placenta = placenta < 10th centile of weight for gestational age; P =0.05; 
*macro- and/or microscopic diagnosis 
 
The comparison of placental weights, CD4 counts and antiretroviral medications are 
shown in Table 4.  The following applies to the antiretroviral treatment provided to the 
classes of cases in Table 4.  In the category:  placental weight <10th centile 32 cases 
(36.4%) received HAART, 38 (43.2%) received PMTCT while 18 (20.4%) received no 
therapy.   In the category:  placental weight >10th to 90th centile 17 (31%) cases received 
HAART, 31 (56.3%) received PMTCT while 7 (12.7%) received no therapy.  None of these 
differences were significant.  In the category:  placental weight >90th centile 6 (31.6%) 
cases received HAART, 9 (47.4%) received PMTCT while 4 (21%) received no therapy.  
None of these differences were significant.  There were four documented cases of 
tuberculosis.  In three of these, the placental weight was below the 10th centile whilst the 
fourth placenta fell in the 10 to 90th centile category. 
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Table 4:  Placental weight and ARV medication 
 CD4 count/mm3 P value 
Placental weight <350 ≥350  
<10th centile 37 (42.0) 51 (58.0) 0.12 
10-90th centile 33 (60.0) 22 (40.0) 0.03 
>90th centile 8 (42.1) 11 (57.9) 0.57 
Data given as n(%) 
 
The comparison of cluster diagnoses to antiretroviral treatment is shown in Table 5. 
 
Table 5:  Cluster diagnoses and ARVs 
Cluster diagnosis HAART PMTCT NIL P value 
Maternal vascular under 
perfusion (MVUP) 
23 (32.8) 34 (48.6) 13 (18.6) NS all 
Placental insufficiency 1 (16.7) 4 (66.6) 1 (16.7) NS all 
Placental abruption*  5 (29.4) 12 (70.6) 0 (0) NS 
Ascending infection 13 (22.4) 32 (55.2) 13 (22.4) NS all 
Hematogenous infection 2 (33.3) 2 (33.3) 2 (33.3) NS all 
Immunological damage 0 (0) 1 (100) 0 (0)  
Small placenta 12 (40) 10 (33.3) 8 (26.7) NS all 
Normal 6 (66.7) 2 (22.2) 1 (11.1) 0.06 
*macro- and/or microscopic diagnosis; p-value comparisons 
 
The cluster diagnoses present in the cases with pre-term birth are shown in Table 6.  
There were 43 cases of pre-term birth at <32 weeks’ gestation and nine cases from 33-
36 weeks’ gestation.  The CD4 counts and antiretroviral treatment of the cases with pre-
term birth are shown in Table 7. 
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Table 6:  Cluster diagnoses and preterm delivery 
Cluster diagnoses Preterm delivery P value 
 ≤32 weeks’ 
gestation 
33-36 weeks’ 
gestation 
 
Maternal vascular under perfusion 
(MVUP) 
11 (73.3) 4 (26.7) 0.44 
Placental insufficiency 3 (100) 0 (0)  
Placental abruption* 3 (60) 2 (40) 0.26 
Ascending infection 17 (89.5) 2 (10.5) 0.58 
Hematogenous infection 3 (100) 0  
Small placenta 6 (85.7) 1 (14.3) 0.89 
*macro- and/or microscopic diagnosis 
 
Table 7:  Preterm delivery, CD4 counts and antiretroviral therapy 
Preterm 
delivery 
CD4 cells/mm3 Antiretroviral therapy 
 <350 ≥350 HAART PMTCT NIL 
≤32 22  22 13 (29.6) 22 (50) 9 (20.4) 
33-36 4 (44.4) 5 (55.6) 4 (44.4) 4 (44.4) 1 (11.2) 
Data given as in n(%); p-value comparisons.  Statistical comparisons were performed on clinical conditions 
and CD4 counts (<350 vs ≥350) as well as preterm delivery and forms of therapy (HAART vs no therapy; 
HAART vs PMTCT; PMTCT vs no therapy and any therapy vs no therapy), but no statistically significant 
differences were found 
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The neonatal data for the study are shown in Table 8. 
 
Table 8: Neonatal data 
Characteristic  Median  (range) 
Gestational age at delivery (weeks) 32 (25–43) 
Apgar score < 7 at 5min n (%) 14 (7.1%) 
Delivery method 
Caesarean section 
Normal vaginal delivery 
 
79 (40.3) 
117 (59.7) 
Birth weight 
≥ 2500g 
1500- 2499g 
<1500g 
 
1840 (180–3860) 
61 (31.1) 
66 (33.7) 
69 (35.0) 
Data given as median (range) or n(%) 
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CHAPTER 5: DISCUSSION 
 
The aim of this retrospective study was to investigate placental changes related to HIV 
infection and to correlate these with maternal characteristics and neonatal outcomes. The 
main histopathological (macro- and microscopic) findings demonstrated small placentae 
(15%) with maternal vascular under-perfusion (36%) and ascending infection (29%).  No 
significant associations between histopathological cluster diagnoses findings and 
maternal ARV therapy or maternal CD4 count (as a marker of immune competence), were 
demonstrated. 
 
The study population was chiefly comprised of young, non-obese, multiparous women of 
whom a surprisingly high percentage (20%) did not receive any form of antiretroviral 
medication.  This is surprising for the metropolitan area of Cape Town as the service has 
been rigorously implemented.  However, many such patients arrive unbooked or with 
intra-uterine deaths. In addition, ARV therapy may be delayed due to maternal illness or 
prescribed, but not taken by the patient due to unexpressed fears.  
 
5.1 Placental pathology findings and clinical outcomes 
 
As stated above, the main placental findings in this study were maternal vascular under-
perfusion (MVUP) (36%), ascending infection (which includes chorioamnionitis) (29%) 
and small placenta (15%).  However there were no significant differences between the 
CD4 counts of <350 and ≥350/ mm3 within the pathological cluster diagnosis groups. 
 
In a prospective single-blinded pilot study conducted by Vermaak et al., (2012), where the 
study population comprised of 91 HIV infected patients, there were associations between 
villitis of unknown aetiology (VUE), decreased placental weights and an increase in the 
number of marginal infarcts [24]. 
 
Various hypotheses have been put forward to explain the increase in chorioamnionitis 
(CAM). In a prospective study undertaken by Ladner et al. in Kigali, examining the role of 
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chorioamnionitis in women treated for sexually transmitted infections in pregnancy, 561 
women were followed up from 24-28 weeks. There was no difference between the study 
and control group, with the study group consisting of HIV seropositive pregnant women 
with low CD4 counts (<200/mm3). It was concluded that CAM was not associated with 
treated sexually transmitted infections. Chorioamnionitis was strongly associated with 
poor pregnancy outcomes in HIV infected women and this was likely due to the deleterious 
effect of HIV in the marginal infarcts in the immunosuppressed group with CD4 count 
<200/mm3 [31]. 
 
These findings highlight the paucity of and conflicting information in the body of evidence 
on the placental findings.  Reporting of pathological diagnoses should be standardized to 
enable findings to be compared.  In this regard the Tygerberg/Stellenbosch group has laid 
great emphasis on specific findings and cluster diagnoses [24].  In addition, more studies 
need to be performed, preferably prospective ones that include a control group.  The ARV 
regimens have changed regularly over a relatively short period of years and the aim is 
that untreated pregnant women will be kept to an absolute minimum.  Nonetheless, in low 
socio-economic circumstances there will always be women who are unaware of their HIV 
infected status and who do not book for care during their pregnancies.  In 1998 Schwartz 
et.al,  performed a prospective study in Thailand and demonstrated an increase in the rate 
of CAM in the HIV positive population compared to HIV negative women, translating to an 
odds ratio of 2:1.  More villitis was also observed and they concluded that there was an 
increase in the inflammatory placental lesions in the HIV population.  However, the 
findings did not translate to an increase in HIV transmission to the baby [22]. 
 
In 2010 Shapiro et.al. investigated the association of HAART and a possible increase in 
stillbirths in a moderately sized, prospective study performed in Botswana [17].  They found 
no association between HAART and stillbirths and postulated that the increased rate seen 
in tertiary centers was linked to the high prevalence of hypertensive diseases seen in 
tertiary care. 
Another longitudinal follow-up study investigated the direct and indirect causes of 
maternal mortality among 499 patients admitted to certain hospitals in Uganda.HIV/AIDS 
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was noted to be the most significant independent predictor of maternal mortality with an 
OR of 5.1.  This was attributed to the lack of antiretroviral medication. Other predictors of 
maternal mortality included lack of blood, not booking and living at a distance of more than 
10km from the hospital in an area with poor infrastructure and transport [32]. 
 
In 2006 Cibulka, emphasised the importance of a viral load of < 1000 copies or 
undetectable in order to reduce transmission rates [33].  In the pre HAART era, 
transmission rates were as high as 25 to 30%.  However, with the introduction of the single 
dose regimen with zidovudine, the transmission rate decreased to 8% [4].  Unfortunately 
this mode of therapy was complicated by an increase in viral mutations which lead to 
resistance to the drug.  The recommendations were therefore changed to include two 
nucleoside reverse transcriptase inhibitors in addition to a protease inhibitor to ensure 
adequate suppression of viral replication.  In the American population described by 
Cibulka, a CD4 count of less than 500 copies per cubic millimeter was viewed as being 
low and hence these patients were started on HAART to suppress the viral load thus 
improving maternal outcomes and also decrease perinatal HIV transmissions.  The 
influence (both direct and indirect) of the various ARV medications on the 
histopathological findings has been poorly described.  Although the index study sought to 
investigate the influence of such therapy on the histopathological findings, it is difficult to 
separate the placental findings from the effects of the stage of the disease itself or 
associated habits and infections.  Substance abuse (smoking and cocaine use in 
particular) and other sexually transmitted infections have been shown to be associated 
with placental damage which translates into increased risk of HIV transmission. This in 
turn, results in increased perinatal morbidity due to preterm birth and chorioamnionitis [33].  
An interesting finding in the index study was that 69% of the babies fell into the low or very 
low birthweight categories.  This is probably because of a large number of pre-term births 
due to medical or iatrogenic reasons.  Another interesting finding was that more placentae 
fell into the normal weight category in the <350/mm3 CD4 count compared to ≥ 350 CD4 
count range/mm3. 
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A large recent retrospective South African study examined 18870 births, of which 3259 
(17%) had HIV infected mothers. They observed a trend in increased perinatal mortality 
in the HIV positive group compared to the negative group. The main causes of morbidity 
were infections, intrauterine growth restriction (IUGR) and antepartum hemorrhage (APH) 
[28].  The findings of the study may have been strengthened by examination of the 
placentae.  Histopathology may confirm or sometimes exclude clinical findings and as 
already stated insufficient attention has been given to placental examination in HIV 
infected pregnancies.  Lack of expertise in histopathological analysis of the placenta and 
cost factors would often preclude this service. 
 
The findings of the index study suggest a low prevalence of smoking (12%).  Although it 
is difficult to substantiate this finding, the placental changes may not be attributed to 
smoking alone.  At the time of the index study, most patients received mono- or dual 
antiretroviral therapy for prevention of mother-to-child transmission as the intended roll-
out of HAART for patients with CD4 counts ≤ 350/mm3 was still to be in the pipeline.  What 
is of concern is that a large percentage (20%) of cases received no ARV medications at 
all.  This could be explained by patient-related factors such as non-attendance and birth 
before arrival as well as non-compliance with prescribed medication.  In addition, if a 
patient presents with an intra-uterine death, prevention of mother-to-child transmission is 
not applicable.  Finally, the failure to prescribe ARV’s by doctors must be considered. 
 
Although the finding of maternal vascular under-perfusion was more frequent in patients 
receiving ARV’s than those not receiving treatment, this difference was not significant. 
 
5.2 Co-morbidities 
 
The commonest comorbidity was pre-eclampsia (42 cases) that was also seen to overlap 
with preterm deliveries, which accounted for 53% of cases. It should be emphasized that 
this study was performed in a tertiary institution.  Pre-eclampsia is a common indication 
for referral and often leads to iatrogenic preterm delivery in order to optimize maternal and 
neonatal outcomes. What is of greater importance is the onset of “spontaneous” preterm 
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birth that may be initiated by ascending infection as noted in the cluster diagnoses of the 
pathology reports. In this study there was no demonstrated evidence of pre-eclampsia 
and HIV or with the various treatment regimens. Previous studies have found no link 
between HAART and pre-eclampsia, however they did find a risk between pre-eclampsia 
and low birth weight infants [34, 35]. In a prospective cohort study performed by Hall et al. 
in 2013, it was reported that pre-eclampsia and gestational hypertension are less common 
in HIV infected women being managed with mono- or triple (HAART) anti-retroviral 
therapy[18]. A prospective observational study done by Landi et.al in 2014, found that 
pregnant women with HIV infection seem to be protected against gestational hypertension 
and pre-eclampsia and this protective effect also remains in a high risk population, such 
as African-American Black ethnic group. The effect is present independently from 
treatment received and virus copies.  The changed immune response present in early 
pregnancy may explain the altered trophoblast invasion resulting in a better placentation 
[35]. 
 
Tuberculosis was observed in four of the placentae, and all patients were found to have 
CD4 counts <350/mm3.  Two patients were not exposed to ARVs. One was given PMTCT 
and the other received HAART. The combination of TB and HIV is well described [36]. 
Diabetes was observed in three of the patients.  All of these had a CD4 count less than 
350/mm3 and did not receive antiretroviral medication. Tuberculosis and HIV are intimately 
related. HIV is driving the TB epidemic in many countries [36]. Looking at the correlation 
between maternal mortality, HIV and TB, Jamison et.al. stated that maternal mortality was 
on the rise with the majority of maternal deaths being due to TB in combination with HIV 
and concluded that treatment of this condition would lead to improved maternal and 
neonatal outcome [37]. 
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HIV infection carries morbidity and mortality risks for both the mother and her unborn child. 
The use of antiretroviral medication has decreased HIV transmission rates to 2%, which 
has resulted in improved neonatal and maternal outcomes in particular in the Western 
Cape Province of South Africa [4].  The histopathological (macro- and microscopic) findings 
of placentae from HIV infected pregnancies need to be strengthened by larger studies 
with controls.  However in order to allow comparison, the categories should be 
standardized, as in this study. 
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CHAPTER 6: APPENDICES 
 
Appendix A:  Maternal Data 
Study no  
Age  
Gravidity  Parity  
BMI  
Smoking YES  NO  
CD4 count  
ARV treatment HAART  PMTCT  NIL 
Co-morbidity 
conditions 
 
 Pre-eclampsia  
Diabetes 
mellitus 
 
Rheumatoid 
disease 
 
Other  
Placental function 
(Doppler) 
 
 >75th centile  
75-95th centile  
>95th centile  
 *AEDF  
*REDF  
Neonatal   
 Gestational 
age at 
delivery 
 
Indication for 
delivery 
Preterm 
labour 
 Pre-
eclampsia 
 Other  
Apgars  
>7 YES  NO  
Birthweight  
Delivery method   
 Normal 
vaginal 
delivery 
 
Caesarean 
section 
 
Instrumental  
*AEDF = Absent end-diastolic flow / *REDF = Reversed end-diastolic flow 
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Appendix B:  Combinations of macroscopic and microscopic placental features 
used for cluster diagnoses 
 
  
Maternal uteroplacental insufficiency (minimum of 3 criteria present) 
   Small placenta (below 10th percentile for gestation) 
   Extensive infarction microscopically 
   Extensive infarction (>20% at term; >15% if premature) 
   Accelerated maturation 
   Distal villous hypoplasia 
Decidual vasculopathy 
   Increased syncytial knots 
   Increase perivillous fibrin 
   Increased extravillous trophoblast (islands) 
Fetal thrombotic vasculopathy (at least 2 criteria present) 
   Cord thrombosis 
   Chorionic plate/stem villous thrombosis 
   Avascular villi 
   Villous-stromal karyorrhexis 
Placental abruption 
   Macroscopic abruption >15% adherent retroplacental hematoma 
   Microscopic abruption (at least 2 criteria present) 
Retroplacental hemorrhage 
      Overlying infarction 
Intravillous hemorrhage 
Treponemal infection (at least 2 criteria present) 
   Diffuse villitis, chronic 
   Delayed maturation 
   Necrotizing funisitis 
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Appendix C:  Indications for placental histology at Tygerberg academic Hospital 
Placental histology must be requested in all the following cases of singleton and multiple 
pregnancies: 
1. All unexplained stillbirths 34+ weeks or more than 2.0 kg.  This excludes cases of 
abruptio placentae, cord prolapse and syphilis.  In case of uncertainty, the placenta 
must be kept with the body for Prof de Jong’s opinion. 
2. Indications of asphyxia in a viable baby.  This group consists of all neonates who 
required resuscitation, unless clearly due to abruptio placentae or prolapse. 
3. Second or higher order midtrimester loss. 
4. Idiopathic preterm labour (gestational age less than 34 weeks or birth weight less 
than 1800 g). 
5. Suspected subclinical chorioamnionitis. 
6. Cases of severe intrauterine growth restriction without antenatal work-up (Doppler 
and ultrasound). 
7. Multiple pregnancies: 
 All applicable indications that would be relevant in singleton pregnancies. 
 All multiple pregnancies with uncertain chorionicity at time of birth. 
8. Congenital abnormalities without prior diagnosis (unless otherwise requested by 
Prof de Jong or Prof Geerts). 
9. Cases of severe pre-eclampsia if requested by Special Care Unit. 
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